Em recrutamento
FASE
Número Europeu 2023-507008-30-00
NCT -
KeyPARTNER
Immunogenicity Profile of Neoadjuvant Keytruda in Combination with Anthracycline versus Carboplatin/PAclitaxel Containing Chemotherapy Regimen for The Treatment of Early-stage, TILs-Positive, Triple-Negative Breast CanceR (KeyPARTNER)
Detalhes
Destaques